JAK2exon 12 mutation-positive myeloproliferative neoplasm associated with recurrent thromboembolism
نویسندگان
چکیده
منابع مشابه
JAK2 exon 12 mutation-positive myeloproliferative neoplasm associated with recurrent thromboembolism
REFERENCES 1. Young JL Jr, Miller RW. Incidence of malignant tumors in U. S. children. J Pediatr 1975;86:254-8. 2. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004;350:1535-48. 3. Jonsson OG, Sartain P, Ducore JM, Buchanan GR. Bone pain as an initial symptom of childhood acute lymphoblastic leukemia: association with nearly normal hematologic indexes. J Pediatr 19...
متن کاملEvaluation of JAK2V617F mutation prevalence in myeloproliferative neoplasm by AS-RT-PCR
Abstract Objective JAK2 is a non-receptor tyrosine kinase that plays a major role in myeloid disorders. JAK2V617F mutation is characterized by a G to T transverse at nucleotide 1849 in exon 12 of the JAK2 gene, located on the chromosome 9p, leading to a substitution of valine to phenylalanine at amino acid position 617 in the JAK2 protein. Methods In this study we evaluated RNA from 89 pati...
متن کاملTwo routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.
Acute myeloid leukemia (AML) may follow a JAK2-positive myeloproliferative neoplasm (MPN), although the mechanisms of disease evolution, often involving loss of mutant JAK2, remain obscure. We studied 16 patients with JAK2-mutant (7 of 16) or JAK2 wild-type (9 of 16) AML after a JAK2-mutant MPN. Primary myelofibrosis or myelofibrotic transformation preceded all 7 JAK2-mutant but only 1 of 9 JAK...
متن کاملMyeloproliferative Neoplasms Associated with Mutation in JAK2V617F and Tyrosine Kinase Inhibitors as Therapeutic Strategy
MPNs including a heterogeneous group of clonal or oligoclonal hamtopathies characterized by proliferation and accumulation of mature myeloid cells. JAK2 tyrosine kinase mutation is the most common molecular lesion identified in 90% of cases. JAK2 is involved in EPO signaling pathway, and mutations in it lead to EPO-independent spontaneous phosphorylation. Most tyrosine kinase inhibitors (TKI) a...
متن کاملMYELOID NEOPLASIA Two routes to leukemic transformation after a JAK2 mutation–positive myeloproliferative neoplasm
1Department of Haematology, Cambridge Institute for Medical Research, Cambridge, United Kingdom; 2Institut Gustave Roussy, Inserm UMR790, Villejuif, France; 3Department of Haematology, Russell’s Hall Hospital, Dudley, United Kingdom; 4Department of Haematology, Dubrava University Hospital, Zagreb, Croatia; 5Centre for Cancer Research and Cell Biology, Queen’s University, Belfast, United Kingdom...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood Research
سال: 2017
ISSN: 2287-979X,2288-0011
DOI: 10.5045/br.2017.52.1.67